Cardio Pharmacogenetics Gene Variation Panel

Test Overview

Metabolizing cardiovascular medication occurs via cytochromes produced in the liver. Because of the interindividual variability in metabolizing cardiovascular medication, the dosing of a certain medication can produce different results for patients. Part of this variability can be attributed to genetic factors that affect the activity of cytochromes, the rate of metabolizing medication, and ultimately the efficacy of the prescribed medication.
Thus, using PGx testing determines a patient’s genetic makeup, as it pertains to drug metabolism, transportation and utilization, and offers healthcare providers insight into a patient’s predicted response to a prescribed medication, and improve the precision of treatment.

Depends on laboratories and patient population, Cardio Pharmacogenetics Gene Variation Panel might contain from several to a large number of targets including ABCB1, ABCG2, APOE, CYP2C, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP4F2, F2, F5, ITGB3, MTHFR, SLCO1B1, VKORC1. PGx testing for cardiovascular medication provides genetic information that optimizes medication regimens for patients with heart disease. Healthcare providers can use PGx as a tool to better design a personalized treatment plan for their patients without having to take the trial-and-error approach, which can reduce the event of adverse drug reactions. Therefore, PGx enables safer, more effective, and cost-effective treatment by using genetic information that would help predict drug response, and further guide optimal drug and dose selection. 

In addition, to above genes and variation the cardiology PGX panel will include genetic variation of coagulation factors FV, FII and MTHFR used for thrombotic genetic risk evaluation as well as APOE genetic variation for arteriosclerosis and cardiovascular disease risk assessment and Alzheimer’s disease risk assessment. The genetic variations (mutations) of the above listed genes are tested using PCR based TaqMan® genotyping assay or next generation sequencing assay. 

Clinical Utility:

• Evaluation of drug therapy used for cardiovascular diseases and disorders 
• Evaluation of thrombotic risk and thrombophilia related diseases
• Evaluation of arteriosclerosis and cardiovascular disease risk assessment